Tags : Tanezumab

Biotech

Pfizer and Eli Lilly Report the US FDA Acceptance of

Shots: The US FDA has accepted to review a BLA for tanezumab (2.5 mg, SC), being evaluated for patients with chronic pain due to mod. to sev. OA with inadequate pain relief with other analgesics The regulatory submission is based on data from 39 P-I-III clinical studies assessing tanezumab in 18,000 patients, including three P-III […]Read More

Pharma

Pfizer & Eli Lilly Report Results of Tanezumab in Long-Term

Shots: The P-III A4091058 study involves assessing of Tanezumab (2.5 & 5mg, q8w) vs NSAIDS (naproxen 500 mg/celecoxib 100 mg/diclofenac extended release 75 mg, q2d) in 3,021 patients with moderate-to-severe OA in ratio 1:1:1 for 56wks. across globe + 24-week safety follow-up study The P-III A4091058 results: composite 1EPs for safety (3.8% & 7.1% vs […]Read More